Top Companies in Obesity Treatment Market | Strategies, In-depth analysis, Statistics by VMR
Obesity is a huge problem in affluent countries as well as low- and middle-income ones. Overweight and obesity, according to a World Health Organization fact sheet, are linked to a variety of diseases and lead to a greater mortality rate than malnutrition.
Coralia.Joe
Market Overview:
The Global Obesity Treatment market is valued at USD 10.18 Billion in 2021 and is projected to attain a value of USD 21.71 Billion by 2028 at a CAGR of 16.5% during the forecast period, 2022–2028. The rising chronic stress among people results in an increase in cortisol levels that is responsible to stimulate the appetite resulting in weight gain and at the same time creating difficulty in losing unwanted pounds. According to Mental Health Foundation's 2018 UK study, in 2017, almost 74% of people felt so stressed that they have been overwhelmed and were not able to cope with it whereas 29% reported that they started drinking and 16% reported that they started smoking. Furthermore, it also estimated that 51% of adults felt stressed and depressed, and 61% reported feeling anxious additionally, it estimated that 46% reported they ate too much unhealthily due to stress which resulted in an increase in the obesity rates among most of the people. Thus the increase in obesity rates due to an increase in stress and depression is anticipated to increase the demand for obesity treatment in the near future.
Obesity is a very complicated health issue induced due to factors such as behavior and genetics. People suffering from obesity are at higher risk for most serious diseases and health conditions, which include hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis, sleep apnea, breathing problems along with mental illnesses such as clinical depression, anxiety, and other mental disorders. As obesity is resulting in various health conditions and people are getting well versed with these adverse effects of obesity is anticipated to augment the growth of the global Obesity Treatment market during the forecast period. However, the high cost of surgery, lack of awareness about the treatments and may hamper the growth of the market in near future. Moreover, the increasing inclination of consumers toward weight-loss surgeries along with increasing healthcare expenditure owing to the increased income of consumers will further support the growth of the Obesity Treatment market.
Following are the top 9 leading companies in the Obesity Treatment market:
|
Company Name |
Revenue in USD |
|
$80 Million |
|
<$5 Million |
|
$67 Billion |
|
$21 Billion |
|
$16 Billion |
|
$31 Billion |
|
$512 Million |
|
$9 Million |
|
<$5 Million |
Vivus is a small pharmaceutical company headquartered in Campbell, California, working in obesity, sleep, and sexual health. The company is developing an erectile dysfunction drug, Avanafil that has completed Phase 3 clinical trials. The drug has been approved for use by the FDA, and will be sold under the trademark name Stendra. The company also developed an obesity drug, Qnexa, a combination of phentermine and topiramate, two existing weight-loss drugs.
Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company's most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease.
Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the largest pharmaceutical company in the world and the leading provider of cancer treatments globally. The company controls the American biotechnology company Genentech, which is a wholly-owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based companies Ventana and Foundation Medicine. is organized into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics. All business areas except Roche Applied Science focus on health care applications, targeting either physicians, hospitals and clinics, or consumers. Applied Science targets research settings in academia and pharmaceutical and biotechnology industries.
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 5 countries. The company manufactures and markets pharmaceutical products and services specifically diabetes care medications and devices. The company is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza.
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures, and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox. Allergan plc was formed in March 2015 when Irish–registered Actavis plc acquired the U.S.–registered Allergan, Inc., and assumed the Allergan name.
Medtronic was established in 1949. Headquartered in the U.S., the company offers innovative services and solutions to hospitals, physicians, clinicians, and patients. The company operates through four operating segments Cardiac & Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. Each group is separated into business divisions that deliver a wide range of medical technologies, therapies, services, and solutions.
Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line. The company has manufactured surgical sutures and wound closure devices since 1887. The company has stood side by side with healthcare professionals around the world, sharing the same passion to improve and save lives. The company is humbled to support customers’ efforts to keep healthcare running during times of unprecedented disruption.
Cousin Surgery imagines, designs manufactures, and distributes innovative implants around the world, to advance visceral surgery and spine surgery. The company relies on unique expertise in the world of implantable textiles and great creativity in the design of implants, in close collaboration with surgeons. The areas of innovation of the company: preserve mobility and reducing postoperative pain.
USGI Medical® is committed to the development of technologies that enable incision-less procedures which help patients return to normal activities and lifestyles faster compared to traditional laparoscopic and open surgery. Utilizing small flexible instruments, the company's technology creates durable and permanent tissue folds to treat a variety of gastrointestinal indications.
Get a Free Sample Here: https://www.vantagemarketresearch.com/obesity-treatment-market-1326/request-sample
For More Information about each of these companies.
Vantage Market Research Report comes up with a detailed analysis of each major player in the industry. The Study provides Global market size & share, Emerging trends, an in-depth analysis of key players, Development opportunities, Sales, Revenue Forecast.
